GLP1R and endothelial dysfunction: For instance, an ongoing clinical trial (NCT02380521) examines the effect of exenatide once weekly, a GLP-1 receptor agonist, on several CV risk markers like subclinical atherosclerosis, endothelial dysfunction, oxidative stress and atherogenic lipoproteins, which are also indicative of potential microvascular complications [81].